Genmab — December 2019

E_L

What advice can you offer to community hematologists and oncologists treating patients with transplant-ineligible NDMM?

Dr. Mateos: Always try to use the best combination first because the best combinations will benefit almost 100% of newly diagnosed myeloma patients. The maximum benefit is obtained from the first line of therapy, and some transplant-ineligible patients with NDMM will receive only one line of therapy. https://i3health.us/news/adding-daratumumab-to-vmp-for-transplant-ineligible

E_L

Genmab article on p 16 http://digitaledition.qwinc.com/publication/?m=53489&l=1&view=issuelistBrowser#{"issue_id":"641494","page":16}

E_L

Glaxo’s myeloma Dreamm turns into a nightmare https://www.evaluate.com/vantage/articles/news/trial-results/glaxos-myeloma-dreamm-turns-nightmare

peter12

Maybe this link is better ? http://digitaledition.qwinc.com/publication/?i=641494&ver=html5&p=16

Solsen

CAR-T https://finance.yahoo.com/news/gileads-second-car-t-treatment-161320198.html

nohope

Spændende, endda skrevet så selv jeg kunne læse det, tak.

JKY_VH

ser godt ud peter12:-)

Solsen

Kunne man håbe, at Novartis er den anonyme køber https://ml-eu.globenewswire.com/Resource/Download/3d403113-b3d8-47e1-b152-6ce5e26c3d60

nohope

Hvorfor vil du gerne se Novartis købe ?

GeorgeBest

Så de kan bruge den til at få Ofa MS hurtigere godkendt, og på markedet...

Solsen

Synes der er en rimelig chance for det. Timing og konkurrencesituationen samt potentialet i ofa i RRMS.

Mcjean

den PR var ikke så dyr før i tiden røg de til 250 mill. men i dag er det vidst meget normalt med 100-125 mill.

Mcjean

Solsen tror du ikke de regner med at få PR?

Solsen

Nej det tror jeg ikke. Så vigtig er den ikke set fra fdas side. Pts kan jo blot bruge ocrelizumab.

bibob

God morgen.

Helge_LarsenPI-redaktør

God morgen.

transalp

Go morgen..

Helge_LarsenPI-redaktør

Just a moment...

(www.proinvestor.com)

E_L

I see Genmab is also included in this Blackrock ETF, iShares Genomics Immunology and Healthcare ETF https://www.blackrock.com/us/individual/products/308878/